A new AI tool developed by researchers at Cedars-Sinai is redefining cardiovascular diagnostics. EchoNext uses deep learning to detect signs of transthyretin amyloid cardiomyopathy — a condition often overlooked in heart failure patients — simply by analyzing a standard ECG.
Traditionally, this condition could only be diagnosed through costly and specialized scans. Now, EchoNext can do it in seconds, using data from a 12-lead electrocardiogram, making early diagnosis faster, cheaper, and far more accessible.
The condition affects an estimated 5% of people over 65 with heart failure, yet it often goes undiagnosed until it’s too late. EchoNext brings us closer to earlier interventions — and better patient outcomes.
The study was published in Nature Medicine and marks a promising step toward scalable, AI-powered heart disease screening.
#MarketNews #AIInHealthcare #Cardiology #ECG #EchoNext #DeepLearning #MedicalAI #DigitalHealth #HeartHealth #Transthyretin #NatureMedicine